All In Biotech

Free tool

FAERS Monitor: R-Gene 10

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 016931 or its brand name (R-Gene 10, Arginine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

103

Serious

83

81% of reports

Hospitalization

41

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypotension10
  • off label use8
  • haematuria7
  • vomiting7
  • diarrhoea6
  • nausea6
  • cardiac disorder5
  • drug ineffective5
  • fatigue5
  • malaise5
  • atrial fibrillation4
  • cough4
  • pyrexia4
  • renal impairment4
  • acidosis hyperchloraemic3

Reports by year received

View as table
YearReports
20062
20072
20081
201010
20113
20126
20131
20144
20154
20167
20173
20183
20197
20203
20218
20228
20239
20247
202513
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acidosis hyperchloraemicSignal31037.6339.32,146
haematuriaSignal741.820.4240
cardiac disorderSignal510.94.636
hypotensionSignal1010.25.675
renal impairmentSignal49.73.723
atrial fibrillationSignal48.43.219
vomitingSignal73.01.58
cough42.91.13
pyrexia42.40.92
malaise52.31.03
diarrhoea61.90.92
off label use81.91.03
nausea61.50.71
fatigue51.30.60
drug ineffective50.80.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.